Van ECK Associates Corp Has $3.80 Million Stock Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)

Van ECK Associates Corp grew its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 21.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 71,691 shares of the biopharmaceutical company's stock after buying an additional 12,565 shares during the quarter. Van ECK Associates Corp owned approximately 0.07% of Cytokinetics worth $3,802,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. lifted its holdings in Cytokinetics by 138.7% in the third quarter. Harbor Capital Advisors Inc. now owns 42,526 shares of the biopharmaceutical company's stock valued at $2,245,000 after buying an additional 24,712 shares during the period. Pinnacle Associates Ltd. lifted its holdings in Cytokinetics by 1.8% in the third quarter. Pinnacle Associates Ltd. now owns 258,358 shares of the biopharmaceutical company's stock valued at $13,641,000 after buying an additional 4,494 shares during the period. New York State Teachers Retirement System lifted its holdings in Cytokinetics by 1.4% in the third quarter. New York State Teachers Retirement System now owns 113,800 shares of the biopharmaceutical company's stock valued at $6,009,000 after buying an additional 1,600 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Cytokinetics by 68.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 22,630 shares of the biopharmaceutical company's stock valued at $1,195,000 after buying an additional 9,159 shares during the period. Finally, Nisa Investment Advisors LLC raised its holdings in Cytokinetics by 2.9% in the third quarter. Nisa Investment Advisors LLC now owns 15,062 shares of the biopharmaceutical company's stock worth $795,000 after purchasing an additional 430 shares during the period.

Insider Buying and Selling

In related news, CEO Robert I. Blum sold 11,500 shares of Cytokinetics stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $55.17, for a total transaction of $634,455.00. Following the completion of the sale, the chief executive officer now owns 399,412 shares of the company's stock, valued at approximately $22,035,560.04. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Cytokinetics news, CEO Robert I. Blum sold 11,500 shares of the business's stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $55.17, for a total value of $634,455.00. Following the completion of the sale, the chief executive officer now owns 399,412 shares of the company's stock, valued at $22,035,560.04. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director B Lynne Parshall sold 5,000 shares of the business's stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $55.20, for a total transaction of $276,000.00. Following the completion of the sale, the director now directly owns 20,600 shares of the company's stock, valued at $1,137,120. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 70,236 shares of company stock valued at $3,800,944. Company insiders own 3.40% of the company's stock.

Cytokinetics Stock Performance

Shares of Cytokinetics stock traded up $2.14 during trading on Friday, hitting $57.98. 1,719,834 shares of the stock were exchanged, compared to its average volume of 988,072. The stock has a market capitalization of $6.82 billion, a price-to-earnings ratio of -10.78 and a beta of 0.78. The company has a fifty day moving average price of $54.10 and a 200-day moving average price of $55.57. Cytokinetics, Incorporated has a 1-year low of $30.68 and a 1-year high of $110.25. The company has a current ratio of 10.39, a quick ratio of 10.39 and a debt-to-equity ratio of 5.93.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.09). The firm had revenue of $0.46 million for the quarter, compared to the consensus estimate of $1.21 million. Cytokinetics's revenue was up 22.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.35) EPS. As a group, equities analysts predict that Cytokinetics, Incorporated will post -5.2 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on CYTK shares. JMP Securities reissued a "market outperform" rating and set a $78.00 price target on shares of Cytokinetics in a research report on Wednesday, September 4th. Cantor Fitzgerald reissued an "overweight" rating on shares of Cytokinetics in a research report on Friday, October 18th. JPMorgan Chase & Co. lifted their price target on shares of Cytokinetics from $65.00 to $71.00 and gave the stock an "overweight" rating in a research report on Thursday, September 5th. The Goldman Sachs Group cut shares of Cytokinetics from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $85.00 to $60.00 in a research report on Tuesday, August 13th. Finally, Needham & Company LLC reissued a "buy" rating and set a $72.00 price target on shares of Cytokinetics in a research report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, Cytokinetics currently has a consensus rating of "Moderate Buy" and a consensus price target of $83.67.

Cytokinetics Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.